Emerging New Technologies in Pharamcogenomics: Rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1)

Pharmacology and Therapeutics

Volumn 126, Issue 1, 2010, Pages 69-81

  Ishikawa, Toshihisa ^a,b   Sakurai, Aki ^a,b   Hirano, Hiroyuki ^a   Lezhava, Alexander ^b   Sakurai, Minoru ^a   Hayashizaki, Yoshihide ^b  

^a TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

ABC transporter; ABCB1 (P glycoprotein); personalized medicine; pharmacogenomics; QSAR analysis; Single nucleotide polymorphisms (SNP)

Indexed keywords

ABC TRANSPORTER; ACEMETACIN; ACETYLSALICYLIC ACID; AMINO ACID; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BEPRIDIL; BETAMETHASONE; CORTISONE; DEXAMETHASONE; DIGOXIN; DILTIAZEM; EPIRIZOLE; FENDILINE; GEFITINIB; GENOMIC DNA; IBUPROFEN; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN 1; NAPROXEN; NICARDIPINE; NICORANDIL; NIFEDIPINE; PAROXETINE; PINACIDIL; PREDNISOLONE; PRENYLAMINE; TROGLITAZONE; UNINDEXED DRUG; VERAPAMIL;

AMINO ACID ANALYSIS; ANALYTIC METHOD; DEPRESSION; DNA ISOLATION; DRUG ABSORPTION; DRUG BINDING SITE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; ENZYME SPECIFICITY; GENE TECHNOLOGY; GENETIC VARIABILITY; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS;

ADENOSINE TRIPHOSPHATASES; GENETIC VARIATION; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77649273238     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2010.01.005     Document Type: Review

References (93)

1. Allabi A.C., Horsmans Y., Issaoui B., and Gala J.L. Single nucleotide polymorphisms of ABCB1 (MDR1) gene and distinct haplotype profile in a West Black African population. Eur J Clin Pharmacol 61 (2005) 97-102
2. Aller S.G., Yu J., Ward A., Weng Y., Chittaboina S., Zhuo R., et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323 (2009) 1718-1722
3. Ambudkar S.V., Lelong I.H., Zhang J., and Cardarelli C. Purification and reconstitution of human P-glycoprotein. Methods Enzymol 292 (1998) 492-504
4. Ambudkar S.V., Kim I.W., and Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27 (2006) 392-400
5. Andersson T., Flockert D.A., Goldstein D.B., Huang S.M., Kroetz D.L., Milos P.M., et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 78 (2005) 559-581
6. Aomori T., Yamamoto K., Oguchi-Katayama A., Kawai Y., Ishidao T., Mitani Y., et al. Rapid SNP detection of the cytochrome P-450 (CYP) 2C9 and the vitamin K oxide reductase (VKORC1) gene for the warfarin dose adjustment by Smart-Amplification process version 2. Clin Chem 55 (2009) 804-812
7. Balaresque P.L., Ballereau S.J., and Jobling M.A. Challenges in human genetic diversity: demographic history and adaptation. Human Mol Genet 16 (2007) R134-R139
8. Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., DiNola A., and Haak J.R. Molecular dynamics with coupling to an external bath. J Chem Phys 81 (1984) 3684-3690
9. Borst P., and Oude Elferink R. Mammalian ABC transporters in health and disease. Ann Rev Biochem 71 (2002) 537-592
10. Case, D.A., Darden, T.A., Cheatham, T.E.III., Simmerling, C.L., Wang, J., Duke, R.E., Luo, R., Merz, K.M., Wang, B., Pearlman, D.A., Crowley, M., Brozell, S., Tsui, V., Gohlke, H., Mongan, J., Hornak, V., Cui, G., Beroza, P., Schafmeister, C., Caldwell, J.W., Ross, W.S., and Kollman, P.A. (2004), University of California, San Francisco.
11. Chowbay B., Li H., David M., and Lee E.J. Meta-analysis of the influence of MDR1 c3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol 60 (2005) 159-171
12. Dawson R.J., and Locher K.P. Structure of a bacterial multidrug ABC transporter. Nature 443 (2006) 180-185
13. Dean M., Rzhetsky A., and Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11 (2001) 1156-1166
14. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348 (2003) 538-549
15. Fiser A., Do R.K., and Sali A. Modeling of loops in protein structures. Protein Sci 9 (2000) 1753-1773
16. Frueh F.W., Amur S., Mummaneni P., Epstein R.S., Aubert R.E., DeLuca T.M., et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28 (2008) 992-998
17. Gottesman M.M., and Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580 (2006) 998-1009
18. Gow J.M., Hodges L.M., Chinn L.W., and Kroetz D.L. Substrate-dependent effects of human ABCB1 coding polymorphisms. J Pharmacol Exp Ther 325 (2008) 435-442
19. Green H., Soderkvist P., Rosenberg P., Horvath G., and Peterson C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12 (2006) 849-854
20. Haselden J.N., and Nicholls A.W. Personalized medicine progresses. Nat Med 12 (2006) 510-511
21. Hirano H., Kurata A., Onishi Y., Sakurai A., Saito H., Nakagawa H., et al. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharm 3 (2006) 252-265
22. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97 (2000) 3473-3478
23. Holland I.B., Cole S.P.C., Kuchler K., and Higgins C.F. ABC Proteins: From Bacteria to Man (2003), Academic Press, Amsterdam
24. Horinouchi M., Sakaeda T., Nakamura T., Morita Y., Tamura T., Aoyama N., et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 19 (2002) 1581-1585
25. Horsmann S., and Binder E.B. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 124 (2009) 57-73
26. Hoshi K., Takakura H., Mitani Y., Tatsumi K., Momiyama N., Ichikawa Y., et al. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 13 (2007) 4974-4983
27. Hüebner C., Petermann I., Browning B.L., Shelling A.N., and Ferguson L.R. Triallelic single nucletotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol Biomarkers Prev 16 6 (2007) 1185-1192
28. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 17 (1992) 463-468
29. Ishikawa T. Multidrug resistance: genomics of ABC transporters. In: Cooper D.N. (Ed). Nature Encyclopedia of the Human Genome Vol. 4 (2003), Nature Publishing Group, London 154-160
30. Ishikawa T., Tsuji A., Inui K., Sai Y., Anzai N., Wada M., et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 5 (2004) 67-99
31. Ishikawa T., Sakurai A., Kanamori Y., Nagakura M., Hirano H., Takarada Y., et al. High-speed screening of human ATP-binding cassette transporter function and genetic polymorphisms: new strategies in pharmacogenomics. Methods Enzymol 400 (2005) 485-510
32. Ishikawa T., Tamura A., Saito H., Wakabayashi K., and Nakagawa H. Pharmacogenomics of the human ABC transporter ABCG2: from functional evaluation to drug molecular design. Naturwissenschaften 92 (2005) 451-463
33. Itoda M., Saito Y., Komamura K., Ueno K., Kamakura S., Ozawa S., et al. Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. Drug Metab Pharmacokinet 17 (2002) 566-571
34. Jaquenoud Sirot E., Knezevic B., Morena G.P., Harenberg S., Onega B., Crettol S., et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenomics of clozapine. J Clin Psychopharmacol 29 (2009) 277-288
35. Jobling M., Hurles M.E., and Tyler-Smith C. Human Evolutionary Genetics: Origins (2004), Peoples and Diseases, Garland Science, New York, Abingdon
36. Johne A., Kopke K., Gerloff T., Mai I., Rietbrock S., Meisel C., et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72 (2002) 584-594
37. Kafka A., Sauer G., Jaeger C., Grundmann R., Kreienberg R., Zeillinger R., et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22 (2003) 1117-1121
38. Kalow W., Meyer U.A., and Tyndale R.F. Pharmacogenomics (2001), Marcel Dekker, New York
39. Kato M., Fukuda T., Serretti A., Wakeno M., Okugawa G., Ikenaga Y., et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 398-404
40. Kawai Y., Kikuchi T., Mitani Y., Kogo Y., Itoh M., Usui K., et al. Sensitive detection of EGFR mutations using a competitive probe to suppress background in the SMart Amplification Process. Biologicals 36 (2008) 234-238
41. Kerb R., Hoffmeyer S., and Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2 (2001) 51-64
42. Kim R.B., Leake B.F., Choo E.F., Dresser G.K., Kubba S.V., Schwarz U.I., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001) 189-199
43. Kim M.J., Huang S.M., Meyer U.A., Rahman A., and Lesko L.J. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 49 (2009) 138-146
44. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 (2007) 525-528
45. Klein I., Sarkadi B., and Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1461 (1999) 237-262
46. Kroetz D.L., Pauli-Magnus C., Hodges L.M., Huang C.C., Kawamoto M., Johns S.J., et al. Sequence diversity and haplotype structure in the humans ABCB1 (MDR1, multidrug rsistance transporter) gene. Pharmacogenomics 13 (2003) 481-494
47. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 26 (1993) 283-291
48. Leabman M.K., Huang C.C., DeYoung J., Carlson E.J., Taylor T.R., de la Cruz M., et al. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci USA 100 (2003) 5896-5901
49. Leighton J.K., Degeorge J., Jacobson-Kram D., MacGregor J., Mendrick D., and Worobec A. Pharmacogenomic data submission to FDA: non-clinical case studies. Pharmacogenomics 5 (2004) 507-511
50. Leschzinger G.D., Andrew T., Pirmohamed M., and Johnson M.R. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharm J 7 (2007) 154-179
51. Lesko L.J. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin Pharmacol Ther 84 (2008) 301-303
52. Loo T.W., Bartlett M.C., and Clarke D.M. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein. Biochemistry 44 (2005) 10250-10258
53. Lown K.S., Mayo R.R., Leichman A.B., Hsiao H.L., Turgeon D.K., Schmiedlin-Ren P., et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62 (1997) 248-260
54. Macphee I.A., Fredericks S., Tai T., Syrris P., Carter N.D., Johnston A., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74 (2002) 1486-1489
55. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 (2004) 13-33
56. Masuda S., Uemoto S., Hashida T., Inomata Y., Tanaka K., and Inui K. Effect of intestinal P-glycoprotein on daily tacrolims trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 68 (2000) 98-103
57. Mitani Y., Lezhava A., Kawai Y., Kikuchi T., Oguchi-Katayama A., Kogo Y., et al. Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat Methods 4 (2007) 257-262
58. Onufriev A., Bashford D., and Case D.A. Modification of the generalized Born model suitable for macromolecules. J Phys Chem B 104 (2000) 3712-3720
59. Ozawa S., Soyama A., Saeki M., Fukushima-Uesaka H., Itoda M., Koyano S., et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19 (2004) 83-95
60. Ruano G., Collins J.M., Dorner A.J., Wang S.J., Guerciolini R., and Huang S.M. Pharmacogenomic data submission to the FDA: clinical pharmacology case studies. Pharmacogenomics 5 (2004) 513-517
61. Ryckaert J., Ciccotti G., and Berendsen H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys 23 (1977) 327-341
62. Sadee W. Drug therapy and personalized health care: pharmacogenomics in perspective. Pharm Res 25 (2008) 2713-2719
63. Saito S., Iida A., Sekine A., Miura Y., Ogawa C., Kawauchi S., et al. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet 47 (2002) 38-50
64. Saito K., Miyake S., Moriya H., Yamazaki M., Itoh F., Imai K., et al. Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. Clin Biochem 36 (2003) 511-518
65. Saito H., Hirano H., Nakagawa H., Fukami T., Oosumi K., Murakami K., et al. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 317 (2006) 1114-1124
66. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab. Pharmacokinet 20 (2005) 391-414
67. Sakaeda T., Nakamura T., and Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4 (2003) 397-410
68. Sakurai A., Tamura A., Onishi Y., and Ishikawa T. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother 6 (2005) 2455-2473
69. Sakurai A., Onishi Y., Hirano H., Seigneuret M., Obanayama K., Kim G., et al. Quantitative SAR analysis and molecular dynamic simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1. Biochemistry 46 (2007) 7678-7693
70. Salerno R., and Lesko L.J. Pharmacogenomics in drug development and regulatory decision-making: the genomic data submission. Pharmacogenomics 5 (2004) 25-30
71. Salerno R., and Lesko L.J. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5 (2004) 503-505
72. Sali A., and Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234 (1993) 779-815
73. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., and Gottesman M.M. Silent polymorphisms speaks: how they affect pharmacogenomics amd the treatment of cancer. Cancer Res 67 (2007) 9609-9612
74. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55 (2003) 3-29
75. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
76. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72 (2002) 572-583
77. Supek F., and Vlahovicek K. Comparison of codon usage measures and their applicability in prediction of microbial gene expressivity. BMC Bioinformatics 6 (2005) 182-196
78. Tamura A., Watanabe M., Saito H., Nakagawa H., Kamachi T., Okura I., et al. Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: identification of alleles that are defective in porphyrin transport. Mol Pharmacol 70 (2006) 287-296
79. Tamura A., Wakabayashi K., Onishi Y., Takeda M., Ikegami Y., Sawada S., et al. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci 98 (2007) 231-239
80. Tang K., Wong L.P., Lee E.J.D., Chong S.S., and Lee C.G.L. Genomic evidence for recent positive selection at the human MDR1 gene locus. Human Mol Genet 13 (2004) 783-797
81. Tatsumi K., Mitani Y., Watanabe J., Takakura H., Hoshi K., Kawai Y., et al. Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn 10 (2008) 520-526
82. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25 (1997) 4876-4882
83. Toyoda Y., Hagiya Y., Adachi T., Hoshijima K., Kuo M.T., and Ishikawa T. MRP class of human ABC transporters: historiacal background and new research directions. Xenobiotica 38 (2008) 833-862
84. Toyoda Y., Sakurai A., Mitani Y., Nakashima M., Yoshiura K., Nakagawa H., et al. Earwax, osmidrosis, and breast cancer: why does one SNP (538G > A) in the human ABC transporter ABCC11 gene determine earwax type?. FASEB J. 23 (2009) 2001-2013
85. Trepiccho W.L., Williams G.A., Essayan D., Hall S.T., Harty L.C., Shaw P.M., et al. Pharmacogenomic data submission to the FDA: clinical case studies. Pharmacogenomics 5 (2004) 519-524
86. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57 (2008) 203-209
87. Uwai Y., Masuda S., Goto M., Motohashi H., Saito H., Okuda M., et al. Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. J Hum Genet 49 (2004) 40-45
88. Virgintino D., Robertson D., Errede M., Benagiano V., Tauer U., Roncali L., et al. Expression of caveolin-1 in human brain microvessels. Neuroscience 115 (2002) 145-152
89. Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph 8 (1990) 52-56
90. Watanabe J., Mitani Y., Kawai Y., Kikuchi T., Kogo Y., Oguchi-Katayama A., et al. Use of a competitive probe in assay design for genotyping of the UGT1A1 *28 microsatellite polymorphism by the smart amplification process. Biotechniques 43 (2007) 479-484
91. Weiss S.T., McLeod H.L., Flockert D.A., Dolan M.E., Benowitz N.L., Johnson J.A., et al. Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 7 (2008) 568-574
92. Wilke R.A., Lin D.W., Roden D.M., Watkins P.B., Flockhart D., Zineh I., et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6 (2007) 904-916
93. Yoshiura K., Kinoshita A., Ishida T., Ninokata A., Ishikawa T., Kaname T., et al. A SNP in the ABCC11 gene is the determinant of human earwax type. Nat Genet 38 (2006) 324-330